Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bruce Bochner
Northwestern University at Chicago, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Allakos, Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
The investigator has equity interests in and receives payment from Allakos, Inc., an entity generating a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses, which it intends to advance to clinical proof-of-concept. The investigator has intellectual property interests in the molecule Siglec-8 for which Allakos is a likely commericial vehicle. Continued research and development through this grant related to translation and application of this IP and/or other IP with the potential to be licensed to Allakos may result in a perceived conflict of interest.
**Note: Allakos recently went public. See FCOI report # 6476 for report of Allakos interest when non-publicly traded.
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
Allergic diseases and eosinophilic gastrointestinal disorders are not well controlled in a substantial number of patients, resulting in significant morbidity and cost. Prior studies have implicated two particular cell types, eosinophils and mast cells, in the pathogenesis of these disorders, and cancers involving these cells can be fatal. Studies in this grant application will explore whether Siglec-8, a molecule selectively expressed by these two cells, can be targeted for both diagnostic and therapeutic purposes.
Filed on October 03, 2018.
Tell us what you know about Bruce Bochner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Bruce Bochner filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Bruce Bochner | Northwestern University at Chicago | Conflict of Interest | Allakos, Inc. | $500,000 - $549,999 |
| Bruce Bochner | Northwestern University at Chicago | Conflict of Interest | Allakos, Inc. | $10,000 - $19,999 |
| Bruce Bochner | Northwestern University at Chicago | Conflict of Interest | Allakos, Inc. | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.